Ann: Bio-Gene Extends Commercial Development Agreement, page-23

Thats just it Holmes, I reckon that we've gotten stuck seeing BGT without numbers while behind the scenes, Clarke, Evergreen, STK and others are sharpening their spreadsheets and this is now moving quietly into $ territory after years of being pigeonholed in the R&D bucket. eg STK agreement was for scope involving a $17b market with an investment made by them to progress the application process for Qcide. Clarke is paying milestones based on ticking off technicals and regulatory progress. Evergreen are paying a royalty and for the registration process - their use case and market was $2b and growing at 5% CAGR in 2021. None of this happens without CFO's, CEO's etc. from these companies receiving DD reports from their technical people and advice from their commercial people saying they want the advantage that these products will bring to their respective markets (before their competitors get it). A few posts from me today as from this ann today I can see commercialisation whilst early is now a live stream. Next I think is finalisation of STK terms.
Glad to pick up a few sub 10c while we were down here.